Compounds > dexmedetomidine
Page last updated: 2024-08-24

dexmedetomidine and Parkinsonian Disorders

dexmedetomidine has been researched along with Parkinsonian Disorders in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haghdoost-Yazdi, H; Minaei, A1
Durieux, ME; Elias, WJ; Frysinger, RC; Huss, D1

Other Studies

2 other study(ies) available for dexmedetomidine and Parkinsonian Disorders

ArticleYear
Dexmedetomidine attenuates the induction and reverses the progress of 6-hydroxydopamine- induced parkinsonism; involvement of K
    Toxicology and applied pharmacology, 2019, 11-01, Volume: 382

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Progression; Inflammation Mediators; KATP Channels; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-2

2019
Dexmedetomidine and arousal affect subthalamic neurons.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Jul-15, Volume: 23, Issue:9

    Topics: Action Potentials; Analgesics, Non-Narcotic; Arousal; Deep Brain Stimulation; Dexmedetomidine; Humans; Microelectrodes; Neurons; Parkinsonian Disorders; Retrospective Studies; Subthalamic Nucleus

2008